The appalling gulf between access to modern Haematology drugs in New Zealand and treatments available as ‘standard of care’ in other countries is succinctly outlined in a letter crafted by Dr Rodger Tiedemann – and endorsed by Leukaemia & Blood Cancer NZ.
This issue has snowballed over the past decade to become a critical failing in our healthcare system. Kiwis, in particular, living with multiple myeloma have not benefited from any of the considerable global progress over the past decade.
The letter specifically requests the urgent review of Daratumumab as a priority – a copy of the letter sent, can be read here